Results 191 to 200 of about 130,782 (308)

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma. [PDF]

Pigment Cell Melanoma Res
Tellenbach FL, Seiler L, Johnson M, Rehrauer H, Schukla P, Martinez-Gomez J, Stoffel CI, Kamal A, Dummer R, Levesque MP, Eichhoff OM.   +10 more
europepmc   +1 more source

Moderate increase of MET in hepatocytes protects against cholestatic liver injury by promoting an effective antioxidant response

The FEBS Journal, EarlyView.
Moderate overexpression of wild‐type Met in hepatocytes (Alb‐R26Met mouse model) boosts a strong antioxidant response dependent on the glutathione system while impairing TGF‐β signaling in the liver. This leads to improved liver regeneration and protects against DDC‐induced injury, a model for cholestatic disease sharing features with primary ...
Carlos González‐Corralejo, Juan García‐Sáez, María Figueroa‐Fuentes, Annalisa Addante, Cesáreo Roncero, Nerea Lazcanoiturburu, Beatriz Pacheco, Julián Sanz, Cristina Gato, Eva Fernández‐Calderón, María de la O López, Águeda González‐Rodríguez, Almudena Porras, Flavio Maina, Isabel Fabregat, Blanca Herrera, Aránzazu Sánchez   +16 more
wiley   +1 more source

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer. [PDF]

Arch Endocrinol Metab
Finkel I, Korzets Y, Moore A, Coreanu T, Popovtzer A, Shoffel-Havakuk H, Bachar G, Mansour J, Weiss C, Robenshtok E.   +9 more
europepmc   +1 more source

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. [PDF]

Front Pharmacol, 2023
Liu Y, Cheng Y, Huang G, Xia X, Wang X, Tian H.   +5 more
europepmc   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib. [PDF]

JAAD Case Rep
Rallapalle V, Kole L, Pavlidakey P, Bhambhvani P, Harada S, Ravindran A, Goyal G.   +6 more
europepmc   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

Fulminant Myocarditis Presenting With Refractory Ventricular Fibrillation During BRAF/MEK Inhibitor Therapy. [PDF]

JACC Case Rep
Lalario A, Rubbo FM, Bassetto G, Mazzaro E, Pinamonti M, Bussani R, Sinagra G, Stolfo D.   +7 more
europepmc   +1 more source

Spatiotemporal dynamics of β‐arrestin‐mediated Src activation in 5‐HT7 receptor signaling pathway

The FEBS Journal, EarlyView.
GPCRs induce distinct cellular responses via G protein‐ or β‐arrestin‐mediated signaling pathways. This study revealed that β‐arrestin‐biased 5‐HT7R ligand induces slow, sustained Src activation, contrasting with transient G protein‐mediated activation.
Hyunbin Kim, Yong Woo Lee, Huimin Lee, Eunseo Park, Jieon Lee, Hae Nim Lee, Kyeong‐Man Kim, Hyunah Choo, Jihye Seong   +8 more
wiley   +1 more source

Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. [PDF]

Mol Cancer Ther
Mughees M, Tacam M, Tan AW, Pitner MK, Iles LR, Hu X, Villodre ES, Debeb BG, Kogawa T, Lim B, Layman RM, Woodward WA, Ueno NT, Tripathy D, Krishnamurthy S, Qi Y, Pusztai L, Wang J, Gandhi V, Bartholomeusz G, Bartholomeusz C.   +20 more
europepmc   +1 more source